Safety profile of recombinant canarypox HIV vaccines-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety profile of recombinant canarypox HIV vaccines

Published:2004-01 Issue:5-6 Volume:22 Page:704-713
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Bruyn Guy de,Rossini Anthony J,Chiu Ya-Lin,Holman Drienna,Elizaga Marnie L,Frey Sharon E,Burke Donald,Evans Thomas G,Corey Lawrence,Keefer Michael C

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference25 articles.

1. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity;Shiver;Nature,2002

2. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection;Musey;N. Engl. J. Med.,1997

3. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS vaccine evaluation group protocol 022A;Gupta;J. Acquir. Immune. Defic. Syndr.,2002

4. The AIDS Vaccine Evaluation Group Protocol 022 Team. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. J Infect Dis 2001;183(4):563–70.

5. Vaccine adverse events in the new millennium: is there reason for concern?;Ward;Bull. World Health Organ.,2000

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Viral Vector Vaccines against Bluetongue Virus;Microorganisms;2020-12-25

2. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines;PLOS Medicine;2020-02-24

3. Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies;PLOS ONE;2018-04-24

4. Current Peptide and Protein Candidates Challenging HIV Therapy beyond the Vaccine Era;Viruses;2017-09-29

5. HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response;Expert Review of Vaccines;2016-02-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3